Bireociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的Ⅲ期临床试验(BRIGHT-2研究中期分析)[1] Bireociclib是一种新型的选择性CDK4/6抑制剂,无论是作为单一疗法还是与内分泌治疗(ET)联合使用,都显示出有前景的临床活性和可管理的耐受性。中国医学科学院...
[2].Cobleigh M, Yardley DA, Brufsky AM, et al. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 Mar 1;26(5):1105-1113.[3].Rugo HS, Rumble RB, Macrae E, B...
近期,发表在美国癌症协会(ACS)期刊CA:A Cancer Journal for Clinicians上的重磅综述,全面探讨了HR+/HER2-乳腺癌的病理和分子特征以及内分泌抵抗机制,总结了早期和转移性HR+/HER2-乳腺癌目前和新兴的治疗方法,包括内分泌疗法(ET)、靶向治疗、化疗、抗体药物偶...
[8]Modi S, Jacot W, Iwata H, et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): UpDate: survival results of the randomized, phase 3 DESTINY-Breast04 study. 2023 ESMO ...
第三个重要研究当属DESTINY-Breast06(DB06)[4],这项研究探索了在晚期未曾接受过化疗的内分泌耐药HR+/HER2低表达和HER2超低表达晚期乳腺癌患者中,更早线使用ADC的可能性。 因此,我认为这是今年ASCO公布的三个最重要的研究数据,当我们将其与过去几年间发布的所有研究数据相结合时,能够让我们有更深入的了解,并...
参考来源:‘U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer’,新闻发布。Gilead Sciences, Inc.;2022年10月11日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治...
参考文献: Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena.https://www.onclive.com/view/targeted-agents-expand-the-hr-her2-metastatic-breast-cancer-treatment-arena
在2024 年的 ASCO 大会中,多项摘要文章报道了 HR+/HER2- 早期乳腺癌患者的复发风险评估或分析结果。 1 Short-term risk of recurrence in patients (pts) with HR+/HER2- early breastcancer (EBC) treated with endocrine therapy (ET) in randomized clinicaltrials (RCTs): A meta-analysis. ...
[3]、Cristofanilli, Massimo et al. “Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 random...
辉瑞(Pfizer)近日宣布,发表于同行评议期刊的真实世界证据(RWE)证明:在HR+/HER2-转移性乳腺癌(mBC)女性患者中,与来曲唑(letrozole)相比,靶向抗癌药Ibrance(爱博新®,通用名:palbociclib,哌柏西利)联合来曲唑一线治疗改善了真实世界无进展生存期(rwPFS)和总生存期(OS)。这些发现是首次在常规临床实践中对一种CDK4...